Cargando…

A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer’s Disease: Results from the MOPEAD Project

BACKGROUND: For care planning and support, under-detection and late diagnosis of Alzheimer’s disease (AD) is a great challenge. Models of Patient-Engagement for Alzheimer’s Disease (MOPEAD) is an EU-funded project aiming at testing different strategies to improve this situation. OBJECTIVE: To make a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wimo, Anders, Belger, Mark, Bon, Jaka, Jessen, Frank, Dumas, Annette, Kramberger, Milica G., Jamilis, Laura, Johansson, Gunilla, Rodrigo Salas, Adrián, Rodríguez Gómez, Octavio, Sannemann, Lena, Stoekenbroek, Malou, Gurruchaga Telleria, Miren, Valero, Sergi, Vermunt, Lisa, Waterink, Lisa, Winblad, Bengt, Visser, Peter Jelle, Zwan, Marissa, Boada, Mercè
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543247/ https://www.ncbi.nlm.nih.gov/pubmed/34420954 http://dx.doi.org/10.3233/JAD-210303

Ejemplares similares

General practitioners’ attitude toward early and pre‐dementia diagnosis of AD in five European countries—A MOPEAD project survey
por: Sannemann, Lena, et al.
Publicado: (2021)

Complementary pre‐screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project
por: Boada, Mercè, et al.
Publicado: (2021)

Identification of undiagnosed dementia cases using a web‐based pre‐screening tool: The MOPEAD project
por: Rodrigo, Adrián, et al.
Publicado: (2021)

Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
por: Ortiz Zuñiga, Angel Michael, et al.
Publicado: (2020)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023)

Cost of Diagnosing and Treating Cognitive Complaints: One-year Cost-evaluation Study in a Patient Cohort from a Slovenian Memory Clinic
por: Županič, Eva, et al.
Publicado: (2022)

32 años de diplomacia mexicana : de los principios a la acción comercial
por: Gurruchaga Rodríguez, Miren Edurne Sabina
Publicado: (2015)

Influencia de la cultura organizacional en la rotación del docente en Bachilleres Valle de Orizaba
por: Gurruchaga Rodríguez, Miren Edurne Sabina
Publicado: (1999)

Quantifying and Describing the Natural History and Costs of Alzheimer’s Disease and Effects of Hypothetical Interventions
por: Wimo, Anders, et al.
Publicado: (2020)

Changes in mortality trends amongst common diseases during the COVID-19 pandemic in Sweden
por: Axenhus, Michael, et al.
Publicado: (2021)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework
por: Green, Colin, et al.
Publicado: (2019)

Exploring the prevalence and variance of cognitive impairment, pain, neuropsychiatric symptoms and ADL dependency among persons living in nursing homes; a cross-sectional study
por: Björk, Sabine, et al.
Publicado: (2016)

Changes in dementia diagnoses in Sweden during the COVID-19 pandemic
por: Axenhus, Michael, et al.
Publicado: (2022)

Changes in Brain-Health Related Modifiable Risk Factors in Older Adults After One Year of COVID-19-Restrictions
por: Waterink, Lisa, et al.
Publicado: (2022)

Sex, Neuropsychiatric Profiles, and Caregiver Burden in Alzheimer’s Disease Dementia: A Latent Class Analysis
por: Rosende-Roca, Maitée, et al.
Publicado: (2022)

Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis
por: Aye, Sandar, et al.
Publicado: (2023)

Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
por: Cano, Amanda, et al.
Publicado: (2023)

PCSK9 inhibition: the way forward in the treatment of dyslipidemia
por: Stoekenbroek, Robert M., et al.
Publicado: (2015)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer’s disease dementia
por: Belger, Mark, et al.
Publicado: (2018)

Extracellular vesicles, the emerging mirrors of brain physiopathology
por: Cano, Amanda, et al.
Publicado: (2023)

Managing Clinical Trials for Alzheimer’s Disease During the COVID-19 Crisis: Experience at Fundació ACE in Barcelona, Spain
por: Abdelnour, Carla, et al.
Publicado: (2020)

Caregiver Burden in Alzheimer's Disease: Differential Associations in Adult-Child and Spousal Caregivers in the GERAS Observational Study
por: Reed, Catherine, et al.
Publicado: (2014)

Changes in spontaneous overt motor execution immediately after observing others’ painful action: two pilot studies
por: Pool-Goudzwaard, Annelies, et al.
Publicado: (2018)

The worldwide costs of dementia 2015 and comparisons with 2010
por: Wimo, Anders, et al.
Publicado: (2017)

The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
por: Rosende-Roca, Maitee, et al.
Publicado: (2021)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

How to deal with missing longitudinal data in cost of illness analysis in Alzheimer’s disease—suggestions from the GERAS observational study
por: Belger, Mark, et al.
Publicado: (2016)

Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain
por: Benaque, Alba, et al.
Publicado: (2020)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia
por: Alonso-Lana, Silvia, et al.
Publicado: (2020)

Cost-effectiveness models for Alzheimer’s disease and related dementias: IPECAD modeling workshop cross-comparison challenge
por: Handels, Ron L.H., et al.
Publicado: (2023)

Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways
por: Cano, Amanda, et al.
Publicado: (2021)

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges
por: Cano, Amanda, et al.
Publicado: (2021)

Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
por: Morató, Xavier, et al.
Publicado: (2022)

Stromal vascular fraction therapy for knee osteoarthritis: a systematic review
por: Boada-Pladellorens, Anna, et al.
Publicado: (2022)

Comentario al original ’Adaptación y viabilidad de la versión telemática de la escala Fugl Meyer para la evaluación de pacientes tras accidentes cerebrovasculares
por: Avellanet, Merce, et al.
Publicado: (2022)

Estimating parent-specific QTL effects through cumulating linked identity-by-state SNP effects in multiparental populations
por: Maurer, A, et al.
Publicado: (2017)

Challenges for New Adopters in Pre-Surgical Margin Assessment by Handheld Reflectance Confocal Microscope of Basal Cell Carcinoma; A Prospective Single-center Study
por: Richarz, Nina Anika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gf1fr52opgl4vutpg0kfldckir